Verona Pharma (VRNA) Stock Price, News & Analysis

Company Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $34.51 to $36.10
• 50-Day Range: $27.49 to $39.87
• 52-Week Range: $11.39 to $40.13
• Volume: 893,958 shs
• Average Volume: 930,252 shs
• Market Capitalization: $2.81 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.83
• Consensus Rating: Buy

Verona Pharma Stock Analysis - MarketRank™

Verona Pharma scored higher than 69% of companies evaluated by MarketBeat, and ranked 643rd out of 965 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Verona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Verona Pharma has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Verona Pharma are expected to grow in the coming year, from ($2.11) to ($1.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Verona Pharma is -18.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Verona Pharma is -18.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Verona Pharma has a P/B Ratio of 11.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.35% of the outstanding shares of Verona Pharma have been sold short.

Short Interest Ratio / Days to Cover

Verona Pharma has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Verona Pharma has recently decreased by 5.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Verona Pharma does not currently pay a dividend.

Dividend Growth

Verona Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.35% of the outstanding shares of Verona Pharma have been sold short.

Short Interest Ratio / Days to Cover

Verona Pharma has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Verona Pharma has recently decreased by 5.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.96

News Sentiment

Verona Pharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Verona Pharma this week, compared to 3 articles on an average week.

Search Interest

Only 13 people have searched for VRNA on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.

MarketBeat Follows

13 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 63% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Verona Pharma insiders have sold 2,549.13% more of their company's stock than they have bought. Specifically, they have bought $188,928.00 in company stock and sold $5,004,952.00 in company stock.

Percentage Held by Insiders

Only 4.80% of the stock of Verona Pharma is held by insiders.

Percentage Held by Institutions

85.88% of the stock of Verona Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VRNA Stock Analysis - Frequently Asked Questions

How have VRNA shares performed this year?

Verona Pharma's stock was trading at $19.88 at the beginning of 2024. Since then, VRNA stock has increased by 75.8% and is now trading at $34.94.
View the best growth stocks for 2024 here.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) released its earnings results on Monday, November, 4th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.12. The business earned $5.62 million during the quarter, compared to the consensus estimate of $2.31 million.

When did Verona Pharma IPO?

Verona Pharma (VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Who are Verona Pharma's major shareholders?

Top institutional shareholders of Verona Pharma include RA Capital Management L.P. (6.27%), Maverick Capital Ltd. (5.24%), Frazier Life Sciences Management L.P. (4.23%) and Eventide Asset Management LLC (3.02%). Insiders that own company stock include David Zaccardelli, Mark W Hahn, Orbimed Advisors Llc, Kathleen A Rickard, Claire Poll, David R Ebsworth, Martin Edwards and Lisa Deschamps.
View institutional ownership trends.

How do I buy shares of Verona Pharma?

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma investors own include Cisco Systems (CSCO), Philip Morris International (PM), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Home Depot (HD) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 11/04/2024
• Today: 11/18/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VRNA
• CUSIP: N/A
• CIK: 1657312
• Web: www.veronapharma.com
• Phone: 011-44-0-2032834200
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $43.83
• High Stock Price Target: $64.00
• Low Stock Price Target: $33.00
• Potential Upside/Downside: +22.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-54,370,000.00
• Net Margins: N/A
• Pretax Margin: -2,698.40%
• Return on Equity: -79.54%
• Return on Assets: -43.49%

Debt

• Debt-to-Equity Ratio: 0.93
• Current Ratio: 13.03
• Quick Ratio: 12.88

Sales & Book Value

• Annual Sales: $5.62 million
• Price / Sales: 513.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.10 per share
• Price / Book: 11.57

Miscellaneous

• Outstanding Shares: 80,440,000
• Free Float: 76,103,000
• Market Cap: $2.89 billion
• Optionable: Optionable
• Beta: 0.42